ZJY-54
ZJY-54 is an orally active dual-target inhibitor of EGFR/LSD1, with IC50 values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity[1].
Product Specifications
UNSPSC
12352211
Target
EGFR; Histone Demethylase
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
COC1=C(C=C(C(N2C[C@@H](CC2)N(C)C)=C1)NC(C=C)=O)NC3=NC(C4=CN(C([2H])([2H])[2H])C5=CC=CC=C54)=CC=N3
Molecular Formula
C29H30D3N7O2
Molecular Weight
514.64
References & Citations
[1]Zhang J, et al. Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers. J Med Chem. 2025 Mar 13;68 (5) :5954-5972.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC051429-500 1x 500 µL
E-Cadherin / CD324 (Intercellular Junction Marker) (4A2), CF405M conjugate, 0.1mg/mL
Sign In for Pricing
View Details 